ESMO Breast 2023 | Prognostic biomarkers of immunotherapy efficacy in breast cancer

Justin Balko, PharmD, PhD, Vanderbilt University Medical Center, Nashville, TN, discusses how specific biomarkers such as circulating tumor DNA (ctDNA) can serve as indicators of whether a patient is benefiting from a certain treatment regimen. Dr Balko emphasizes, however, that further randomized clinical trials need to be conducted to determine positive or negative predictive values of other prognostic biomarkers. This interview took place at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.